[Coagulation system in patients with blood malignancies treated with estrogens in the course of cytostatic therapy].
OBJECTIVE
To evaluate the effect of estrogen gestagenic drugs (EGD) on blood coagulation in patients with blood malignancies treated by polychemotherapy.


METHODS
32 females of reproductive age treated with ovarioprotector marvelon during cytostatic therapy. The following indices were determined: activated partial thrombin time, prothrombin index of the ethanol test, fibrinogen and antithrombin III levels, factor XIIa dependent time of fibrinolysis, thrombin time. Dopplerography of the lower limb vessels was carried out.


RESULTS
No significant alterations in coagulograms of the patients treated with cytostatics in combination with EGD were recorded.


CONCLUSIONS
It is safe to use EGD as ovarioprotectors in females with hematological malignancies in hypercoagulation.
Ignashina
E V
EV
Vasil'ev
S A
SA
Pivnik
A V
AV
Shilin
D E
DE
Margolin
O V
OV
Kozhurin
S V
SV
D000293:Adolescent; D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects*; D001777:Blood Coagulation / Q000187:drug effects; D001779:Blood Coagulation Factors / Q000378:metabolism; D004359:Drug Therapy, Combination; D045166:Estradiol Congeners / Q000627:therapeutic use*; D005260:Female; D005500:Follow-Up Studies; D019337:Hematologic Neoplasms / Q000097:blood* / Q000188:drug therapy; D006801:Humans; D045167:Progesterone Congeners / Q000627:therapeutic use*; D012098:Reproduction / Q000187:drug effects; D016896:Treatment Outcome
D001779:Blood Coagulation Factors; D045166:Estradiol Congeners; D045167:Progesterone Congeners
Sostoianie svertyvaiushcheĭ sistemy krovi u patsientok s onkogematologicheskimi zabolevaniiami, prinimaiushchikh éstrogengestagennye preparaty v period provedeniia tsitostaticheskoĭ terapii.